GUNN & Co INVESTMENT MANAGEMENT INC. Acquires 798 Shares of Eli Lilly and Company (NYSE:LLY)

GUNN & Co INVESTMENT MANAGEMENT INC. increased its holdings in Eli Lilly and Company (NYSE:LLY) by 124.7% in the 4th quarter, Holdings Channel reports. The fund owned 1,438 shares of the company’s stock after buying an additional 798 shares during the quarter. GUNN & Co INVESTMENT MANAGEMENT INC.’s holdings in Eli Lilly and Company were worth $838,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Lipe & Dalton bought a new position in shares of Eli Lilly and Company during the fourth quarter valued at approximately $26,000. Thompson Investment Management Inc. bought a new position in Eli Lilly and Company during the 3rd quarter valued at approximately $27,000. Optiver Holding B.V. purchased a new position in Eli Lilly and Company during the third quarter valued at $36,000. Family CFO Inc bought a new stake in Eli Lilly and Company in the third quarter worth $40,000. Finally, O Brien Wealth Partners LLC boosted its holdings in Eli Lilly and Company by 70.5% in the fourth quarter. O Brien Wealth Partners LLC now owns 75 shares of the company’s stock worth $44,000 after acquiring an additional 31 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Barclays lifted their price target on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 7th. BMO Capital Markets upped their target price on shares of Eli Lilly and Company from $900.00 to $1,001.00 and gave the stock an “outperform” rating in a research note on Wednesday. Morgan Stanley raised their price target on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research report on Friday, February 16th. Truist Financial upped their price objective on Eli Lilly and Company from $850.00 to $892.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, The Goldman Sachs Group lifted their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a report on Thursday, April 11th. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $757.95.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $734.97 on Friday. The company has a quick ratio of 0.73, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. The stock has a market capitalization of $698.52 billion, a PE ratio of 108.24, a price-to-earnings-growth ratio of 1.50 and a beta of 0.37. The firm’s 50 day moving average price is $761.06 and its 200-day moving average price is $671.38. Eli Lilly and Company has a twelve month low of $419.80 and a twelve month high of $800.78.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Tuesday, April 30th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The business had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. During the same period last year, the firm earned $1.62 earnings per share. The company’s quarterly revenue was up 26.0% on a year-over-year basis. Equities research analysts expect that Eli Lilly and Company will post 13.83 EPS for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.